GE Healthcare (Barrington, Illinois) said it has completed the acquisition of CHCA Computer Systems (Montreal, Quebec), an operating room management and analytics solutions provider.
CHCA develops the Opera software application designed to increase productivity and patient satisfaction in the OR by providing real-time data to support the decision making and management of surgical procedures.
Terms of the acquisition were not disclosed.
GE noted that the acquisition aligns with its industrial Internet strategy and its recent commitment to invest in businesses that enhance the company's software footprint. The deal marks GE's second healthcare acquisition in software this year, following the acquisition of API Healthcare.
"A key tenet of our industrial Internet investment is addressing new and pressing operational and productivity challenges facing healthcare," said Jan De Witte, president/CEO of GE's healthcare IT business. "In the operating room, the epicenter of today's hospital, better efficiency in turn benefits patients by reducing waiting times, preventing cancellations, and increasing patient throughput. CHCA's Opera solution complements our current OR and perioperative software portfolio and will allow us to deliver a more integrated offering that better connects the workflow throughout the OR, using a mix of software, real-time data and powerful analytics to help drive better outcomes for patients."
In other dealmaking news:
• Stryker (Kalamazoo, Michigan) said it has completed its acquisition of Berchtold Holding (Schaffhausen, Switzerland), a company that sells healthcare equipment including surgical tables, equipment booms, and surgical lighting systems. The deal, valued at $172 million, was first reported in February.
Stryker says the transaction is expected to be neutral to its 2014 earnings per share excluding acquisition, integration-related, and intangible amortization charges.
• Eternity Healthcare (Phoenix), a medical device and diagnostic company with a focus on diabetes management, reported that it signed a letter of intent to license technologies from Kinexus Theranostics (Vancouver, British Columbia).
Kinexus says that using blood or tissue samples, the whole parameters of diabetes are illustrated against respective kinase action. This technology utilizes a number of cellular proteins known as kinases in the blood, several years before any changes have occurred with blood sugar levels. Based on the changes to those proteins, one can decide to change their diet and exercise, the company said. The test is designed to detect diabetes far earlier than any currently available test on the market, according to Kinexus. If proper diet is taken, the disease can be prevented, the firm noted.
• Arsenal Capital Partners (New York), a private equity firm that invests in middle market healthcare, specialty industrial, and financial services companies, reported the acquisition of Synchrogenix (Wilmington, Deleware), a regulatory writing and related services firm. Synchrogenix provides services to medical device companies as well as to pharmaceutical and biotechnology companies. The firm will be merged into Certara, a technology-enabled drug development and drug safety consultancy that Arsenal acquired in December.